Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases

“Rounding Third Base and Heading Home”: Arthritis & Rheumatology in 2024

“…Some of the concerns raised in the ACR comments included the cost to authors to publish manuscripts with immediate ("gold") OA, the potential for this requirement to hurt authors who are less well funded, and the downstream financial consequences of drastic reductions in subscription revenues to journals, such as A&R (and to their parent organizations, such as the ACR). Some journals will decide to publish a high volume of articles to make up for financial shortfalls; however, the Expert perspective: Immune checkpoint inhibitors and rheumatologic complications Simms, 2020 9 Expert perspectives on clinical challenges: expert perspectives: Challenges in scleroderma Arora and Rovin, 2022 10 Expert perspective: An approach to refractory lupus nephritis Nocturne and Mariette, 2023 11 Expert perspective: Challenges in Sjögren disease Patel and Stone, 2022 12 Expert perspective: Management of antineutrophil cytoplasmic antibody-associated vasculitis Case et al, 2022 13 Recognizing racial bias and promoting diversity in the rheumatology workforce Grayson et al, 2022 14 VEXAS syndrome and disease taxonomy in rheumatology Rome and Kesselheim, 2023 15 Biosimilar competition for Humira is here: Signs of hope despite early hiccups Dellaripa et al, 2023 16 The climate emergency and the health of our patients: The role of the rheumatologist Syversen et al, 2023 17 Therapeutic drug monitoring: A tool to optimize treatment of inflammatory joint diseases Calabrese et al, 2023 18 "Burnout" coupled with workforce shortages spells trouble: Innovative solutions are essential for more satisfying rheumatology practice Monach, 2024 19 Complement Taubmann et al, 2023 20 CAR-T cell treatment in systemic lupus erythematosus Crow et al, 2024 21 Standing on shoulders: Interferon research, from viral interference to lupus pathogenesis and treatment Hile and Werth, 2024 22 Understanding the role of type I IFN in cutaneous lupus and dermatomyositis: toward better therapeutics * CAR-T, chimeric antigen receptor T cell; IFN, interferon; VEXAS, vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome.…”